Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.63 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.63 |
| ▸ | NR1H4 | Q96RI1 | 10/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891955 | 0.96 | CYSLTR1 (0.63) | GRM2CYSLTR1NR1H4CREBBPNPC1 | |
| SCHEMBL2891330 | 0.93 | GRM2 (0.61) | GRM2CYSLTR1MRGPRX4MEN1KMT2A | |
| SCHEMBL2892010 | 0.92 | CYSLTR1 (0.53) | GRM2CYSLTR1CREBBPNPC1RAB9A | |
| SCHEMBL10740242 | 0.91 | CYSLTR1 (0.73) | GRM2CYSLTR1SMN1; SMN2MRGPRX4 | |
| SCHEMBL3163137 | 0.91 | CYSLTR1 (0.65) | GRM2CYSLTR1CREBBPNFKB1MRGPRX4 | |
| SCHEMBL2888457 | 0.88 | CYSLTR1 (0.53) | GRM2CYSLTR1CREBBPNPC1RAB9A | |
| SCHEMBL2891835 | 0.88 | CYSLTR1 (0.58) | GRM2CYSLTR1NR1H4CREBBPNPC1 | |
| SCHEMBL2896513 | 0.88 | GRM2 (0.58) | GRM2CYSLTR1CREBBPMRGPRX4 | |
| SCHEMBL2888217 | 0.88 | CYSLTR1 (0.51) | GRM2CYSLTR1MRGPRX4 | |
| SCHEMBL481005 | 0.88 | CYSLTR1 (0.68) | GRM2CYSLTR1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678794-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678794-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678794-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1817296-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| EP-1817296-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006057869-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | LTB4R, LTB4R2, CYSLTR1 | GRM2 15/4885CYSLTR1 3/4885NR1H4 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.